Takeda to Present Research Advances in Rare Lysosomal Storage Disorders at 16th Annual WORLDSymposium 2020
Takeda Pharmaceutical Company Limited announced that it will feature 11 presentations, including 10 posters, and one oral presentation highlighting its ongoing studies and commitment to rare lysosomal storage disorders at the 16th annual WORLDSymposium™ 2020 in Orlando, Florida, February 10-13. Presentations and other company activities will focus on Takeda’s continued research and development efforts in lysosomal storage disorders (LSDs) including Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II), type 1 Gaucher disease, Fabry disease and metachromatic leukodystrophy (also known as MLD).
Takeda is also supporting, through an educational grant, a satellite symposium on building a better roadmap for care of Gaucher patients and sponsoring a satellite symposium on peripheral, central and autonomic neurodegenerative consequences in Lysosomal Diseases, as well as sponsoring a booth (Booth #100) in the WORLDSymposium exhibit hall.
“Each year, we look forward to supporting the lysosomal storage disorder community at WORLDSymposium, a unique, global congress that enables us to collaborate with the world’s leading LSD experts to discuss the latest advancements in treating diseases with a high unmet need,” said Donatello Crocetta MD, Global Medical Head, Rare Immunology and Rare Metabolic Franchises in a press release. “Takeda remains dedicated to the rare disease community and collaborating with those who share our goal of improving the lives of patients and families faced with rare disease, including LSDs.”
Read the full press release here.